These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

358 related items for PubMed ID: 29363389

  • 1. Real-World Analysis of Dispensed IUs of Coagulation Factor IX and Resultant Expenditures in Hemophilia B Patients Receiving Standard Half-Life Versus Extended Half-Life Products and Those Switching from Standard Half-Life to Extended Half-Life Products.
    Tortella BJ, Alvir J, McDonald M, Spurden D, Fogarty PF, Chhabra A, Pleil AM.
    J Manag Care Spec Pharm; 2018 Jul; 24(7):643-653. PubMed ID: 29363389
    [Abstract] [Full Text] [Related]

  • 2. Real-World Analysis of Dispensed International Units of Coagulation Factor VIII and Resultant Expenditures for Hemophilia A Patients: A Comparison Between Standard Half-Life and Extended Half-Life Products.
    Chhabra A, Fogarty PF, Tortella BJ, Spurden D, Alvir J, McDonald M, Hodge J, Pleil AM.
    Manag Care; 2018 Oct; 27(10):39-50. PubMed ID: 30309448
    [Abstract] [Full Text] [Related]

  • 3. A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States.
    Aledort L, Milligan S, Watt M, Booth J.
    J Manag Care Spec Pharm; 2020 Apr; 26(4):492-503. PubMed ID: 32223610
    [Abstract] [Full Text] [Related]

  • 4. The Australian experience with switching to extended half-life factor VIII and IX concentrates: On behalf of the Australian Haemophilia Centre Directors' Organisation.
    Brennan Y, Parikh S, McRae S, Tran H.
    Haemophilia; 2020 May; 26(3):529-535. PubMed ID: 32243027
    [Abstract] [Full Text] [Related]

  • 5. Real-World Amount of Clotting Factor Concentrates Dispensed and Annual Medical Expenditures for Japanese Patients with Hemophilia B.
    Fukutake K, Togo K, Xu L, Markson LE, Alvir JMJ, Winburn I, Karumori T.
    J Blood Med; 2023 May; 14():649-661. PubMed ID: 38143791
    [Abstract] [Full Text] [Related]

  • 6. A single centre retrospective study of low dose prophylaxis with extended half-life factor IX for severe haemophilia B.
    Rampotas A, Desborough MJR, Raza-Burton S, Taylor S, Wilkinson A, Hall GW, Shapiro S, Curry N.
    Haemophilia; 2020 Mar; 26(2):278-281. PubMed ID: 32083769
    [Abstract] [Full Text] [Related]

  • 7. Real-world outcomes associated with standard half-life and extended half-life factor replacement products for treatment of haemophilia A and B.
    Chhabra A, Spurden D, Fogarty PF, Tortella BJ, Rubinstein E, Harris S, Pleil AM, Mellor J, de Courcy J, Alvir J.
    Blood Coagul Fibrinolysis; 2020 Apr; 31(3):186-192. PubMed ID: 32271314
    [Abstract] [Full Text] [Related]

  • 8. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia.
    Croteau SE, Cheng D, Cohen AJ, Holmes CE, Malec LM, Silvey M, Thornburg CD, Wheeler AP, Kouides PA, Raffini LJ, Neufeld EJ.
    Haemophilia; 2019 Jul; 25(4):668-675. PubMed ID: 30993845
    [Abstract] [Full Text] [Related]

  • 9. Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients with Haemophilia B Without Inhibitors.
    Pochopien M, Tytuła A, Toumi M, Falk A, Martone N, Hakimi Z, Eriksson D.
    Adv Ther; 2024 Jun; 41(6):2307-2323. PubMed ID: 38652439
    [Abstract] [Full Text] [Related]

  • 10. Real-world outcomes with recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis: Longitudinal follow-up in a national adult cohort.
    O'Donovan M, Bergin C, Quinn E, Singleton E, Roche S, Benson J, Bird R, Byrne M, Duggan C, Gilmore R, Ryan K, O'Donnell JS, O'Connell NM.
    Haemophilia; 2021 Jul; 27(4):618-625. PubMed ID: 33939224
    [Abstract] [Full Text] [Related]

  • 11. Pharmacodynamics of eftrenonacog-alfa (rFIX-Fc) in severe hemophilia B patients: A real-life study.
    Atsou S, Furlan F, Duchemin J, Ellouze S, Sourdeau É, Launois A, Roussel-Robert V, Stieltjes N, Combe S, Fontenay M, Curis E, Jourdi G.
    Eur J Pharmacol; 2021 Jan 15; 891():173764. PubMed ID: 33249076
    [Abstract] [Full Text] [Related]

  • 12. Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B.
    Wang C, Young G.
    Haemophilia; 2018 May 15; 24(3):414-419. PubMed ID: 29405496
    [Abstract] [Full Text] [Related]

  • 13. Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis.
    Hermans C, Marino R, Lambert C, Mangles S, Sommerer P, Rives V, Maro G, Malcangi G.
    Adv Ther; 2020 Jun 15; 37(6):2988-2998. PubMed ID: 32333327
    [Abstract] [Full Text] [Related]

  • 14. Real-World Effectiveness of rFIXFc Prophylaxis in Patients with Haemophilia B Switched from Standard Half-Life Therapy in Three European Countries.
    Funding E, Lowe G, Poulsen LH, Shapiro S, Oldenburg J, Eriksson D, Falk A, Rich C.
    Adv Ther; 2023 Sep 15; 40(9):3770-3783. PubMed ID: 37351812
    [Abstract] [Full Text] [Related]

  • 15. Cost of patients with hemophilia A treated with standard half-life or extended half-life FVIII in Spain.
    Kim HK, Peral C, Rubio-Rodríguez D, Rubio-Terrés C.
    Expert Rev Pharmacoecon Outcomes Res; 2021 Apr 15; 21(2):315-320. PubMed ID: 32597317
    [Abstract] [Full Text] [Related]

  • 16. In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates.
    Preijers T, Bukkems L, van Spengler M, Leebeek F, Cnossen M, Mathôt R.
    Eur J Clin Pharmacol; 2021 Aug 15; 77(8):1193-1200. PubMed ID: 33624121
    [Abstract] [Full Text] [Related]

  • 17. Real-World Amount of Clotting Factor Products and Non-Factor Products Dispensed and Annual Medical Expenditures for Japanese Patients with Haemophilia A.
    Bingo M, Fukutake K, Togo K, Xu L, Alvir JMJ, Winburn I, Karumori T.
    Drugs Real World Outcomes; 2024 Sep 15; 11(3):541-552. PubMed ID: 39127822
    [Abstract] [Full Text] [Related]

  • 18. Switching from standard to extended half-life FVIII prophylaxis in haemophilia A: Comparison of factor product use, bleed rates and pharmacokinetics.
    Nummi V, Lehtinen AE, Iorio A, Szanto T, Lassila R.
    Haemophilia; 2022 Nov 15; 28(6):e237-e244. PubMed ID: 35939628
    [Abstract] [Full Text] [Related]

  • 19. Real-world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years.
    Shapiro A, Chaudhury A, Wang M, Escobar M, Tsao E, Barnowski C, Feng J, Jain N, Quon DV.
    Haemophilia; 2020 Nov 15; 26(6):975-983. PubMed ID: 33012060
    [Abstract] [Full Text] [Related]

  • 20. Surgical outcomes in patients with haemophilia A or B receiving extended half-life recombinant factor VIII and IX Fc fusion proteins: Real-world experience in the Nordic countries.
    Lehtinen AE, Baghaei F, Astermark J, Holme PA.
    Haemophilia; 2022 Sep 15; 28(5):713-719. PubMed ID: 35575446
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.